QNCX
Quince Therapeutics, Inc.
Healthcare · Biotechnology · NMS
$1.01
Data: 2026-05-22
✗ ETHICAL FAIL
MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$21M
Total market value of the company
0.00
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Quince Therapeutics, Inc.
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
1.4% PASS
Debt must be below 33% of total assets
Cash Ratio
86.4% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-62.5%
Historical annualised return based on price data
Days in State
12
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-26 | LUCA BENATTI | Director | 50,000 | $173,500 | |
| 2025-12-10 | THYE DIRK | Chief Executive Officer | 739,885 | — | |
| 2025-12-05 | HANNAH BRENDAN | Chief Operating Officer | 27,551 | $25,012 | |
| 2025-06-18 | RYAN CHARLES S | President | 7,548 | $9,058 | |
| 2025-06-18 | THYE DIRK | Chief Executive Officer | 150,944 | $181,133 | |
| 2025-06-18 | HANNAH BRENDAN | Chief Operating Officer | 37,736 | $45,283 | |
| 2024-08-30 | THYE DIRK | Chief Executive Officer | 154,500 | $107,375 | |
| 2024-08-21 | HANNAH BRENDAN | Chief Operating Officer | 38,924 | $24,166 | |
| 2024-08-20 | RYAN CHARLES S | President | 48,387 | $31,452 | |
| 2024-06-04 | HANNAH BRENDAN | Chief Operating Officer | 56,061 | $30,834 |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-22